The NMPA acceptance of Chance Pharma’s first new drug application advances CXG87, an improved budesonide/formoterol dry powder inhalation therapy, toward potential commercialisation in China. ...
The platform’s creation is rooted in nearly a decade of deep collaboration by a cross-disciplinary team...
Both IV iron therapies are originator products already approved in China and included in the National Reimbursement Drug List (NRDL)...
Demonstrating a Favourable Safety Profile, Robust Immunogenicity, and Promising Preliminary Efficacy...
Delivery of three projects highlights growing adoption of AI-driven, scenario-based applications across enterprise and digital services...
CStone presents preclinical data on three differentiated antibody-drug conjugates, including a dual-target EGFR/HER3 candidate...
He played a key role in the development strategy for dapagliflozin, a leading SGLT-2 inhibitor that has become a global blockbuster in the treatment of metabolic diseases...
The strengthening of routine vaccine sales has contributed to a more balanced revenue mix and enhanced earnings visibility...
The Company has acquired the rights to develop, manufacture, and commercialise CARDAMYST (etripamil) nasal spray in Greater China...
VELSIPITY(R) was approved for marketing by China’s National Medical Products Administration (NMPA) in February this year...
